search
diabetes patients
Trends
- 1Stopping GLP-1 drugs may raise heart attack and stroke risk●Stopping GLP-1 drugs may raise heart attack and stroke risk, study finds
A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.
- 2Pancreatic Cells One Genetic Tweak From Treating Diabetes▼Some Pancreatic Cells Are Just One Genetic Tweak Away From Treating Diabetes https:// fed.brid.gy/r/https://www.wire d.c
New research suggests some pancreatic cells could be converted into insulin-producing cells with a single genetic modification, offering a promising avenue for diabetes treatment. The findings, reported by Wired, point to the potential of reprogramming existing cells to restore insulin function in patients. Scientists and health watchers are sharing the story as a possible step toward new therapies for the disease.
- 3Doctors warn GLP-1 drug users face heat wave health risks▼Amid heat wave, doctors warn of health risks for people taking GLP-1 drugs
Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic may face heightened health risks during the current heat wave. Concerns center on dehydration, as the medications can suppress thirst and appetite, potentially leaving users vulnerable to heat exhaustion and related complications. Patients are being advised to drink water regularly and take precautions in high temperatures as extreme heat persists across many regions.
- 4The End of Insulin Injections? Scientists Push Needle-Free Medicine▼The End of Insulin Injections? How Scientists Are Making Medicine Needle-Free
Scientists are developing needle-free alternatives to insulin injections, a shift that could transform daily treatment for millions of people with diabetes. Reported by National Geographic, the work covers new delivery methods being explored to replace traditional syringes. The topic is drawing attention among patients and medical observers who see it as a potential turning point in how routine medicines are administered.
- 5Diabetes Study Suggests Overly Steady Blood Sugar Has Costs▼Diabetes study finds keeping blood sugar too steady may come at a price
A new diabetes study reports that keeping blood sugar extremely steady may come at a price, challenging the assumption that tighter, more consistent glucose control is always better for patients. The findings are drawing attention from clinicians and people managing diabetes, as they raise questions about how aggressively blood sugar fluctuations should be smoothed out in day-to-day treatment and what trade-offs strict control may involve.
- 6Doctors weigh in on the Ozempic microdosing trend▼Is microdosing Ozempic safe? An obesity medicine doctor on the trend, the risks, and when a low dose makes sense
An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.
- 7Israeli startup DreaMed wins FDA nod for insulin-dosing app▼Israeli startup DreaMed gets FDA approval for app that adjusts insulin doses for Type 2 diabetes
Israeli medtech startup DreaMed Diabetes has received FDA approval for an app that automatically adjusts insulin doses for people with Type 2 diabetes. The clearance lets the company bring its digital insulin-management tool to American patients, extending technology previously aimed at Type 1 diabetes. The news, reported by Calcalist, is being read as a milestone for Israeli digital health firms seeking US market entry.
- 8Israeli startup wins FDA clearance for injection-based diabetes app▼Israeli startup develops injection-based diabetes app, receives FDA clearance
An Israeli startup has received US Food and Drug Administration clearance for an app designed to support people managing diabetes with injections. The digital tool is aimed at helping patients track and handle their insulin treatment more effectively. The clearance marks a regulatory milestone for the young company, and coverage in Israeli media highlights it as another example of the country's health-tech sector gaining traction abroad.
- 9Study links GLP-1 drugs in children to nutritional deficiencies●Interactive: Study links GLP-1 use in children to nutritional deficiencies
A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.
- 10FDA approves Onswik, a once-weekly insulin for type 2 diabetes●The FDA approved Onswik, a once-weekly insulin for type 2 diabetes, but not for type 1. What the trials showed and the s
The FDA has approved Onswik, a once-weekly insulin intended for adults with type 2 diabetes. It was not approved for type 1 diabetes. Coverage highlights what the clinical trials showed about effectiveness and the side effects patients should know about. The approval is drawing attention as a potential convenience shift for diabetes management, reducing injections from daily to weekly.
- 11Heart and Kidney Problems Rise Over Time in Type 2 Diabetes▼Heart and Kidney Problems in Type 2 Diabetes Patients Increase with Time
New coverage reports that heart and kidney complications in patients with type 2 diabetes increase as the disease progresses over time. The finding underscores the cumulative toll of diabetes on cardiovascular and renal health and highlights the importance of long-term monitoring and management of blood sugar, blood pressure and kidney function in affected patients.